Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059963 · ClinicalTrials.gov registry record
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
A clinical trial of Colorectal Cancer and Advanced Adenocarcinoma, sponsored by Universal Diagnostics.
- Recruiting
- Registry status
- 12,000
- Enrollment target
- 1
- Study location
NCT06059963: Recruiting study of Colorectal Cancer and Advanced Adenocarcinoma, sponsored by Universal Diagnostics.
NCT06059963 is a study of Colorectal Cancer and Advanced Adenocarcinoma that is actively recruiting participants, run by Universal Diagnostics. The registered enrollment target is 12,000 participants, above the 1,513-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (693% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06059963, a study of Colorectal Cancer and Advanced Adenocarcinoma, is actively recruiting participants, sponsored by Universal Diagnostics.
- RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Primary Outcome
The primary objective of this study is to determine the sensitivity for CRC and specificity for advanced neoplasia (AN). Advance Neoplasia (AN) is defined as a final diagnosis of CRC or Advanced Precancerous Lesion (APL).
Conditions Studied
Interventions
- DEVICE Signal-C™
Study Locations (1)
Virginia
- Gastroenterology Consultants of SW Virginia - Raonoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2026-12-01 |
What NCT06059963 shows while recruiting
NCT06059963 is an observational study that tracks outcomes without assigning an intervention. Its 12,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,513-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (693% higher).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Signal-C™ is the first listed.
NCT06059963 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06059963 about?
NCT06059963 is a clinical study titled "A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation". To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
What is the current status of trial NCT06059963?
This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2024-01-18. Estimated completion is 2026-12-01.
What conditions does trial NCT06059963 study?
This clinical trial studies the following conditions: Colorectal Cancer, Advanced Adenocarcinoma.
What interventions are being tested in trial NCT06059963?
The interventions under investigation include: Signal-C™ (DEVICE).
Who is sponsoring clinical trial NCT06059963?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06059963 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06059963's enrollment target sits among peer trials
12,000 8th of 381 higher than 374 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
- NCT06354192 · 12,000 participants
Precision Nudging for Hypertension Management: Observational Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI